Imre Berger, Cristiane Schaffitzel, Mick Bailey, David Matthews and Imophoron Ltd.

The work: Testing synthetic COVID-19 VLP vaccine candidates using the thermostable ADDomer© vaccine. The bioengineered ADDomer candidate is a virus-like particle vaccine, created by generating generic VLP and engineering antigens onto the surface. The principle vaccine was tested on the arbovirus, chikungunya, in 2019 and now the ADDomer vaccine candidate is being applied to COVID-19. The G1 B antigen is currently being tested in pre-clinical models, with G2 B and T antigen tests to follow.

Links: Oracle, Imophoron, Unit DX

Funding: EU Advanced Grant, Wellcome Trust, BBSRC

In news and features:

Bristol announced as UK consortium partner providing essential reagents for SARS-CoV-2 research

COVID-19 and pets: What is there to know?

New vaccine platform used to develop COVID-19 candidates

Inside the lab leading Bristol’s coronavirus vaccine effort

Vaccine tests to begin in Bristol after team make coronavirus breakthrough

Coronavirus: How susceptible are pets to the infection?

Bristol University experts rally to fight COVID-19 and search for a vaccine

Oxford COVID-19 vaccine follows its programmed genetic instructions, independent analysis finds